Clinical trials: Gastric Emptying
Diabetes Mellitus, Type 2
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.
- Trial name
- NCT00537719
- Testing
- GSK716155
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity
A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant
This study medicine NNC0487-0111 to improve the treatment options for people living with overweight and obesity or with type 2 diabetes.
- Trial name
- NCT06461039
- Testing
- NNC0487-0111 A, NNC0487-0111 C, Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Diabetic Gastroparesis
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis
The purpose of this study is evaluate the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult men.
- Trial name
- NCT02025751
- Testing
- Metoclopramide Nasal Spray
- Where
- 49 sites in United States
- Volunteers
- 53 people
- Sponsor
- Evoke Pharma
Overweight and Obesity
Evaluation of the Effect of Epitomee Device on Gastric Emptying Rate in Healthy Subjects
Evaluation of the effect of Epitomee Device on Gastric Emptying Rate in healthy subjects
- Trial name
- NCT04485936
- Testing
- Epitomee Device
- Where
- Israel
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Epitomee medical
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese.
- Trial name
- NCT07738614
- Testing
- Eloralintide, Acetaminophen
- Where
- 2 sites in United States, Singapore
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity, Overweight and/or Obesity
A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity
This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity.
- Conditions
- Obesity, Overweight and/or Obesity, Overweight, Drug Interaction
- Trial name
- NCT07508241
- Testing
- PF-08653944, Acetaminophen
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Gastroparesis
Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis
This study is intended to evaluate the potential to relieve the symptoms associated with gastroparesis during 12 weeks of treatment with oral tablets given twice a day of GM-611 5mg, 10mg or placebo to type I or II diabetics who…
- Trial name
- NCT00050882
- Testing
- GM-611
- Where
- 67 sites in United States
- Sponsor
- Chugai Pharma USA
Gastroparesis, Diabetes Mellitus
Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus
The purpose of this study is to evaluate the effect of TZP-102 on gastric emptying rate, gastroparesis symptoms and health-related quality of life in diabetic patients with gastroparesis.
- Trial name
- NCT00889486
- Testing
- TZP-102
- Where
- 23 sites in United States, Denmark and 4 more
- Volunteers
- 92 people
- Sponsor
- Tranzyme, Inc.
Type 2 Diabetes Mellitus
A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes
As exenatide slows the rate at which materials leave the stomach, it is likely to alter the rate of intestinal absorption of oral drugs when administered within a certain timeframe relative to exenatide.
- Trial name
- NCT00517283
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Constipation
Colonic Transit Time Validation Study
The protocol described herein is designed to provide clinical evidence of the substantial equivalence of SmartPill GI Monitoring System (SP) to the Sitzmarks (Konsyl Pharmaceuticals, Easton, MD) radio-opaque markers (ROM).
- Trial name
- CTT (NCT00857363)
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 210 people
- Sponsor
- The SmartPill Corporation
Diabetic Gastroparesis
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered…
- Trial name
- DIGEST (NCT01664637)
- Testing
- 10 mg TZP-102
- Where
- 35 sites in United States, Poland
- Volunteers
- 120 people
- Sponsor
- Tranzyme, Inc.
Overweight or Obesity
The Effect of AMG 133 on Gastric Emptying
The primary objective of the trial is to evaluate the effect of AMG 133 versus placebo on acetaminophen pharmacokinetics (PK), a marker for gastric emptying, in participants living with overweight or obesity.
- Trial name
- NCT07429032
- Testing
- AMG 133, Acetaminophen
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Amgen
Obesity or Overweight
Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection
This is a single-center, open-label, fixed-sequence phase I clinical study to evaluate the effect of GZR18 Injection on gastric emptying and the effect of repeated SC injections of GZR18 Injection on the pharmacokinetics of oral…
- Trial name
- NCT07128888
- Testing
- GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Diabetes Mellitus Type 2
A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes
This 3 arm, placebo-controlled study will investigate the effect of Taspoglutide on gastric emptying in patients with type 2 diabetes.
- Trial name
- NCT00809705
- Testing
- taspoglutide
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Gastroparesis
13C-Spirulina Nitrogen Content GEBT Study
The purpose of this study is to determine whether there is a difference in the human in vivo response to 13C-Spirulina meals manufactured using 13C-Spirulina containing different levels of protein (as measured by %nitrogen).
- Trial name
- NCT04635306
- Testing
- Approved GEBT test meal
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cairn Diagnostics
Nonulcer Dyspepsia
An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia
This study was designed is to examine the idea that GW679769 has an effect on three of the pathophysiological disturbances reported in patients with Functional Dyspepsia (FD): impaired stomach accommodation to a meal, delayed…
- Trial name
- NCT00358410
- Testing
- GW679769 oral tablets
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Diabetes Mellitus Complications
Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
The purpose of this study is to evaluate the effects of multiple dose regimens of relamorelin on vomiting episodes, gastric emptying and gastroparesis symptoms in participants with Type 1 and Type 2 diabetes mellitus and…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
- Trial name
- NCT02357420
- Testing
- Relamorelin
- Where
- 98 sites in United States, Belgium and 5 more
- Volunteers
- 393 people
- Sponsor
- Allergan
Overweight or Obese
A Study of BGM0504 in Overweight or Obese Participants
The purpose of the study is to evaluate the influence of BGM0504 injection on gastric emptying and Pharmacokinetics of metformin and warfarin in overweight or obese participants
- Trial name
- NCT06920056
- Testing
- Paracetamol, Metformin Hydrochloride, Warfarin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Gastroparesis
Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia
Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms associated with gastroparesis.
- Trial name
- NCT00370084
- Testing
- Itopride
- Where
- Australia
- Volunteers
- 25 people
- Sponsor
- Forest Laboratories
Gastroparesis, Diabetic Gastroparesis
Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis
To evaluate the safety and the effectiveness of two doses of metoclopramide nasal spray solution, 10 mg and 14 mg, compared to placebo in reducing the symptoms of diabetic gastroparesis.
- Conditions
- Gastroparesis, Diabetic Gastroparesis, Diabetes, Diabetes Mellitus
- Trial name
- NCT00845858
- Testing
- metoclopramide
- Where
- 65 sites in United States
- Volunteers
- 287 people
- Sponsor
- Evoke Pharma